S&P 500

5.277,51

0,80%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
USOTC
Genmab A S (PK) (GNMSF)
Genmab A S (PK) (GNMSF) Notícias

GNMSF

Genmab A S (PK) (GNMSF)

Genmab A S (PK)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:USOTC:GNMSF

1 2 3 4 5 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
08/05/2024	13:46	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	USOTC:GNMSF	Genmab A S (PK)
10/06/2020	08:34	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	USOTC:GNMSF	Genmab A S (PK)
30/03/2020	18:16	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	USOTC:GNMSF	Genmab A S (PK)
07/02/2020	10:56	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	USOTC:GNMSF	Genmab A S (PK)
14/08/2019	10:27	Edgar (US Regulatory)	Unknown (sec Staff)	USOTC:GNMSF	Genmab A S (PK)
19/07/2019	07:02	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)	USOTC:GNMSF	Genmab A S (PK)
18/07/2019	10:32	Edgar (US Regulatory)	Securities Registration (ads, Immediate) (f-6ef)	USOTC:GNMSF	Genmab A S (PK)
18/07/2019	07:01	Edgar (US Regulatory)	Notice of Effectiveness (effect)	USOTC:GNMSF	Genmab A S (PK)
17/07/2019	20:56	Edgar (US Regulatory)	Registration of Additional Securities (up to 20%, Foreign Issuer) (f-1mef)	USOTC:GNMSF	Genmab A S (PK)
17/07/2019	18:25	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	USOTC:GNMSF	Genmab A S (PK)
16/07/2019	09:55	Edgar (US Regulatory)	Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)	USOTC:GNMSF	Genmab A S (PK)
16/07/2019	09:06	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-1/a)	USOTC:GNMSF	Genmab A S (PK)
15/07/2019	18:02	Edgar (US Regulatory)	Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)	USOTC:GNMSF	Genmab A S (PK)
15/07/2019	15:38	Edgar (US Regulatory)	Certification by the Exchange Approving Securities for Listing (cert)	USOTC:GNMSF	Genmab A S (PK)
12/07/2019	17:53	Edgar (US Regulatory)	Securities Registration (section 12(b)) (8-a12b)	USOTC:GNMSF	Genmab A S (PK)
28/05/2019	17:29	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-1)	USOTC:GNMSF	Genmab A S (PK)
31/07/2014	15:50	GlobeNewswire Inc.	GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL	USOTC:GNMSF	Genmab A S (PK)
23/07/2014	08:11	GlobeNewswire Inc.	Second Quarter 2014 Net Sales Figures for Arzerra(r)	USOTC:GNMSF	Genmab A S (PK)
18/07/2014	10:18	GlobeNewswire Inc.	Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma	USOTC:GNMSF	Genmab A S (PK)
14/07/2014	10:59	GlobeNewswire Inc.	Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen	USOTC:GNMSF	Genmab A S (PK)
07/07/2014	11:23	GlobeNewswire Inc.	Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen	USOTC:GNMSF	Genmab A S (PK)
03/07/2014	10:38	GlobeNewswire Inc.	GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia...	USOTC:GNMSF	Genmab A S (PK)
27/06/2014	15:27	GlobeNewswire Inc.	GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine...	USOTC:GNMSF	Genmab A S (PK)
04/06/2014	03:27	GlobeNewswire Inc.	Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company	USOTC:GNMSF	Genmab A S (PK)
30/05/2014	12:04	GlobeNewswire Inc.	Genmab Announces Ofatumumab Development Plans in RRMS and NMO	USOTC:GNMSF	Genmab A S (PK)
23/05/2014	10:21	GlobeNewswire Inc.	GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line...	USOTC:GNMSF	Genmab A S (PK)
19/05/2014	15:21	GlobeNewswire Inc.	GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs R...	USOTC:GNMSF	Genmab A S (PK)
07/05/2014	12:11	GlobeNewswire Inc.	Genmab Announces Financial Results for the First Quarter of 2014	USOTC:GNMSF	Genmab A S (PK)
01/05/2014	16:09	GlobeNewswire Inc.	Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance	USOTC:GNMSF	Genmab A S (PK)
30/04/2014	08:11	GlobeNewswire Inc.	First Quarter 2014 Net Sales Figures for Arzerra	USOTC:GNMSF	Genmab A S (PK)